Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 8/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 6/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.36 |
| ▸ | CDK2 | P24941 | 6/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.36 |
| ▸ | CDK9 | P50750 | 4/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612506 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10763003 | 0.75 | KDM4E (0.35) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1374158 | 0.75 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1242674 | 0.75 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4251929 | 0.75 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1187755 | 0.75 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| Bromide SCHEMBL1188167 | 0.73 | KDM4E (0.62) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17477291 | 0.71 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL750158 | 0.71 | ALDH1A1 (1.00) | KDM4EALDH1A1SMN1; SMN2HSD17B10DYRK1A | |
| SCHEMBL2268441 | 0.71 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-0228061-A2 | Cephem compounds | Takeda Chemical Industries, Ltd. (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | KDM4E 1566/4885ALDH1A1 4730/4885SMN1; SMN2 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.